444 related articles for article (PubMed ID: 25779662)
21. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
22. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
[TBL] [Abstract][Full Text] [Related]
23. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
[TBL] [Abstract][Full Text] [Related]
24. Higher Expression of
Chen C; Chen Z; Chio CL; Zhao Y; Li Y; Liu Z; Jin Z; Wu X; Wei W; Zhao Q; Li Y
Technol Cancer Res Treat; 2021; 20():15330338211052152. PubMed ID: 34738847
[No Abstract] [Full Text] [Related]
25. The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
Cao L; Zhang W; Liu X; Yang P; Wang J; Hu K; Zhang X; Liu W; He X; Jing H; Yuan X
Sci Rep; 2019 Nov; 9(1):16991. PubMed ID: 31740742
[TBL] [Abstract][Full Text] [Related]
26. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy.
Whitman SP; Kohlschmidt J; Maharry K; Volinia S; Mrózek K; Nicolet D; Schwind S; Becker H; Metzeler KH; Mendler JH; Eisfeld AK; Carroll AJ; Powell BL; Carter TH; Baer MR; Kolitz JE; Park IK; Stone RM; Caligiuri MA; Marcucci G; Bloomfield CD
Leukemia; 2014 Jun; 28(6):1252-1258. PubMed ID: 24326683
[TBL] [Abstract][Full Text] [Related]
27. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
28. Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.
Liu L; Chen R; Zhang Y; Fan W; Xiao F; Yan X
Diagn Pathol; 2015 Jul; 10():109. PubMed ID: 26185105
[TBL] [Abstract][Full Text] [Related]
29. SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia.
Deng A; Ning Q; Zhou L; Liang Y
Sci Rep; 2016 Jun; 6():27694. PubMed ID: 27291931
[TBL] [Abstract][Full Text] [Related]
30. De Novo Acute Myeloid Leukemia in Adults: Suppression of MicroRNA-223 is Independent of LMO2 Protein Expression BUT Associate With Adverse Cytogenetic Profile and Undifferentiated Blast Morphology.
Akhter A; Patel JL; Farooq F; Qureshi A; Taher-Rad MS; Elyamany G; Al-Zahrani AM; Rashid-Kolvear F; Mansoor A
Appl Immunohistochem Mol Morphol; 2015; 23(10):733-9. PubMed ID: 25710580
[TBL] [Abstract][Full Text] [Related]
31. Expression and prognostic impact of lncRNAs in acute myeloid leukemia.
Garzon R; Volinia S; Papaioannou D; Nicolet D; Kohlschmidt J; Yan PS; Mrózek K; Bucci D; Carroll AJ; Baer MR; Wetzler M; Carter TH; Powell BL; Kolitz JE; Moore JO; Eisfeld AK; Blachly JS; Blum W; Caligiuri MA; Stone RM; Marcucci G; Croce CM; Byrd JC; Bloomfield CD
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18679-84. PubMed ID: 25512507
[TBL] [Abstract][Full Text] [Related]
32. Meningioma 1 (MN1) expression: refined risk stratification in acute myeloid leukemia with normal cytogenetics (CN-AML).
Aref S; Ibrahim L; Morkes H; Azmy E; Ebrahim M
Hematology; 2013 Sep; 18(5):277-83. PubMed ID: 23394438
[TBL] [Abstract][Full Text] [Related]
33. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene.
Díaz-Beyá M; Navarro A; Ferrer G; Díaz T; Gel B; Camós M; Pratcorona M; Torrebadell M; Rozman M; Colomer D; Monzo M; Esteve J
Leukemia; 2013 Mar; 27(3):595-603. PubMed ID: 23022987
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.
Kühnl A; Valk PJ; Sanders MA; Ivey A; Hills RK; Mills KI; Gale RE; Kaiser MF; Dillon R; Joannides M; Gilkes A; Haferlach T; Schnittger S; Duprez E; Linch DC; Delwel R; Löwenberg B; Baldus CD; Solomon E; Burnett AK; Grimwade D
Blood; 2015 May; 125(19):2985-94. PubMed ID: 25805812
[TBL] [Abstract][Full Text] [Related]
35. Low miR-34c expression is associated with poor outcome in de novo acute myeloid leukemia.
Yang DQ; Zhou JD; Wang YX; Deng ZQ; Yang J; Yao DM; Qian Z; Yang L; Lin J; Qian J
Int J Lab Hematol; 2017 Feb; 39(1):42-50. PubMed ID: 27577964
[TBL] [Abstract][Full Text] [Related]
36. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
37. MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia.
Ma QL; Wang JH; Yang M; Wang HP; Jin J
J Transl Med; 2018 Mar; 16(1):68. PubMed ID: 29540187
[TBL] [Abstract][Full Text] [Related]
38. Identification of serum miR-34a as a potential biomarker in acute myeloid leukemia.
Huang Y; Zou Y; Lin L; Ma X; Chen H
Cancer Biomark; 2018; 22(4):799-805. PubMed ID: 29945348
[TBL] [Abstract][Full Text] [Related]
39. The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia.
He X; Zhang W; Fu W; Liu X; Yang P; Wang J; Zhu M; Li S; Zhang W; Zhang X; Dong G; Yan C; Zhao Y; Zeng Z; Jing H
Cancer Biomark; 2023; 36(2):103-116. PubMed ID: 36404533
[TBL] [Abstract][Full Text] [Related]
40. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
Gaidzik VI; Schlenk RF; Paschka P; Stölzle A; Späth D; Kuendgen A; von Lilienfeld-Toal M; Brugger W; Derigs HG; Kremers S; Greil R; Raghavachar A; Ringhoffer M; Salih HR; Wattad M; Kirchen HG; Runde V; Heil G; Petzer AL; Girschikofsky M; Heuser M; Kayser S; Goehring G; Teleanu MV; Schlegelberger B; Ganser A; Krauter J; Bullinger L; Döhner H; Döhner K
Blood; 2013 Jun; 121(23):4769-77. PubMed ID: 23632886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
